Company Overview and News

 
Odin Energy Ltd to update on acquisition

2016-07-18 proactiveinvestors.com.au
Odin Energy Ltd (ASX:ODN) has been granted a trading halt by the ASX, pending finalisation of documentation in respect of the company's acquisition of gridComm Pte Ltd (via Austasia Industrial Pty Ltd). gridComm is a technology company that enables data communications across cities’ power grids. The halt will remain in place until the opening of trade on Thursday 21st July 2016, or earlier if an announcement is made to the market.

 
Odin Energy Ltd is Monday's ASX Most Traded with 50 million

2016-06-27 proactiveinvestors.com.au
Odin Energy Ltd (ASX:ODN) is focused on growing its asset base in the oil and gas field.

 
Odin Energy Ltd is Friday's ASX Most Traded late in the session

2016-06-10 proactiveinvestors.com.au
Odin Energy Ltd (ASX:ODN) is focused on growing its asset base in the oil and gas field.

 
Appendix 4G

2016-04-28 asx.com.au

 
 
Update on gridComm

2016-03-31 asx.com.au

 
 
Trading Halt

2016-03-15 asx.com.au

 
Request for Trading Halt

2016-03-15 asx.com.au

 
Response to ASX Price Query

2016-03-15 asx.com.au

 
Response to ASX Price Query

2016-02-29 asx.com.au

 
Rights issue shortfall completed

2016-02-04 asx.com.au

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

19h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

20h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...